目的 通过对苯达莫司汀发表的有关药品不良反应（ADR）的病例报道进行分析，以期为临床安全合理应用提供参考依据。方法 通过检索Web of Science、PubMed、Wiley Online Library、中国知网、万方和维普数据库中有关苯达莫司汀上市后ADR的病例报道，采用回顾性分析方法，对患者的基本情况、ADR发生时间、临床表现、累及器官/系统、处理及转归等信息进行整理分析。结果 共收集27例病例，其中男性16例，女性11例；年龄28～75岁，平均年龄（62.11±9.47）岁。ADR多发生在用药3个周期内，累及7个系统/器官，其中以皮肤及皮下组织与血液系统最为常见（37.04%、33.33%）。结论 苯达莫司汀皮肤及血液系统ADR发生率较高，用药过程应密切监测。此外要特别关注苯达莫司汀长期给药及罕见ADR的监护。

Objective To analyze the adverse drug reactions (ADR) case reports published by bendamustine in order to provide a reference for safety and reasonable use of bendamustine in clinical practice. Methods The cases reports of bendamustine were searched in Web of Science, Pubmed, Wiley Online Library, CNKI, Wanfang, and VIP. The basic patient information, adverse reaction time, clinical characters, involved systems organs, treatment and outcomes were collected and analyzed. Results A total of 27 cases were collected, including 16 males and 11 females. The age ranged from 28 to 75 years, and the overall mean age was (62.11 ±9.47) years. ADR mostly occurred within 3 cycles of medication and involved 7 systems/organs, among which skin, subcutaneous tissue and blood system were the most common (37.04%, 33.33%). Conclusion Bendamustine has a high incidence of ADR in skin and blood system, and the course of medication should be closely monitored. In addition, special attention should be paid to long-term administration of bendamustine and monitoring of rare ADR.

R979.1